Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quabodepistat - Otsuka Pharmaceutical

Next Previous
Drug Profile

Quabodepistat - Otsuka Pharmaceutical

Alternative Names: OPC-167832

Latest Information Update: 11 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical; Otsuka Pharmaceutical Development & Commercialization
  • Class 2 ring heterocyclic compounds; Antibacterials; Antituberculars; Fluorobenzenes; Piperidines; Small molecules
  • Mechanism of Action DprE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 24 Feb 2025 Otsuka Pharmaceutical terminates the phase IIb/c Gates MRI-TBD06-201 trial in Tuberculosis (Newly diagnosed, Combination therapy) in South Africa, Philippines (PO) as data generated do not support investigational regimens being able to achieve the trial objective of identifying a new regimen to treat tuberculosis in 3 months or less(NCT05971602)
  • 19 May 2024 Otsuka Pharmaceutical completes a phase IIb trial in Tuberculosis (Combination therapy) in South Africa (PO) (NCT05221502)
  • 21 Mar 2024 Efficacy and adverse event data from phase II trials in Tuberculosis released by Otsuka Pharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top